Barclays PLC Increases Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Barclays PLC lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 95.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,382,205 shares of the company's stock after purchasing an additional 676,048 shares during the period. Barclays PLC owned about 1.62% of Progyny worth $23,843,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its position in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after buying an additional 1,355 shares during the period. GAMMA Investing LLC grew its position in shares of Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares during the period. Caitlin John LLC raised its position in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after purchasing an additional 3,183 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in Progyny in the fourth quarter valued at $74,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Trading Up 2.1 %

Shares of PGNY traded up $0.46 during trading hours on Wednesday, reaching $22.33. The company had a trading volume of 661,753 shares, compared to its average volume of 1,739,233. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $33.84. The firm has a 50 day simple moving average of $21.93 and a 200-day simple moving average of $18.94. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 38.50, a PEG ratio of 2.39 and a beta of 1.33.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PGNY shares. JPMorgan Chase & Co. increased their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Canaccord Genuity Group increased their price objective on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. Bank of America boosted their target price on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Finally, BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a report on Monday, March 31st. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.